X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.57M | 1.77M | 1.97M | 28.81M | 1.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57M | 1.77M | 1.97M | 28.81M | 1.43M |
| Cost of Revenue | 364.00K | 351.00K | 326.00K | 4.72M | 302.00K |
| Gross Profit | 2.20M | 1.41M | 1.65M | 24.09M | 1.13M |
| SG&A Expenses | 7.38M | 8.19M | 9.53M | 15.02M | 15.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.47M | 24.37M | 28.21M | 38.25M | 37.15M |
| Operating Income | -23.90M | -22.61M | -26.23M | -9.44M | -35.72M |
| Income Before Tax | -23.93M | -29.85M | -25.70M | 316.00K | -39.56M |
| Income Tax Expenses | 0.00 | -30.00K | 37.00K | 34.00K | 258.00K |
| Earnings from Continuing Operations | -23.93M | -29.82M | -25.74M | 282.00K | -39.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.93M | -29.82M | -25.74M | 282.00K | -39.82M |
| EBIT | -23.90M | -22.61M | -26.23M | -9.44M | -35.72M |
| EBITDA | -23.68M | -22.39M | -25.88M | -8.97M | -35.44M |
| EPS Basic | -0.22 | -0.69 | -3.47 | 0.04 | -5.89 |
| Normalized Basic EPS | -0.14 | -0.36 | -2.17 | 0.03 | -3.66 |
| EPS Diluted | -0.22 | -0.69 | -3.47 | 0.04 | -5.89 |
| Normalized Diluted EPS | -0.14 | -0.36 | -2.17 | 0.03 | -3.66 |
| Average Basic Shares Outstanding | 110.56M | 43.27M | 7.41M | 6.84M | 6.76M |
| Average Diluted Shares Outstanding | 110.56M | 43.27M | 7.41M | 6.87M | 6.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |